Magnolol
Research reviewed: Up until 03/2026
Magnolol is a dietary supplement with 9 published peer-reviewed studies involving 480 participants, researched for Anti-inflammatory Activity, Anxiety & Stress, Metabolic Health and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Anti-inflammatory Activity
ModerateAnxiety & Stress
ModerateMetabolic Health
ModerateGut Health
StrongResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Anti-inflammatory Activity
To characterize anti-inflammatory mechanisms of Magnolol in macrophages
Study Type
In vitro study
Purpose
To characterize anti-inflammatory mechanisms of Magnolol in macrophages
Dose
10-100 μM Magnolol
Participants
RAW 264.7 macrophage cells
Duration
24 hours
Results
Magnolol inhibited IκB-α degradation and NF-κB nuclear translocation, reduced MAPK phosphorylation, and suppressed COX-2, iNOS, IL-6, and TNF-α expression in LPS-activated macrophages.
How They Measured It
NF-κB pathway analysis, MAPK activation, COX-2/iNOS expression, cytokine profiling
To evaluate Magnolia bark extract containing Magnolol on inflammatory markers in adults with metabolic syndrome
Study Type
Randomised controlled trial
Purpose
To evaluate Magnolia bark extract containing Magnolol on inflammatory markers in adults with metabolic syndrome
Dose
200 mg Magnolia extract (standardized 10% Magnolol) daily
Participants
90 adults with metabolic syndrome
Duration
12 weeks
Results
Magnolia extract significantly reduced CRP (−22%), IL-6, TNF-α, and oxidized LDL compared to placebo. NF-κB activity in PBMCs was significantly lower in the treatment group.
How They Measured It
CRP, IL-6, TNF-α, oxidized LDL, NF-κB in PBMCs
Anxiety & Stress
To evaluate Magnolol for anxiety and stress in healthy adults
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Magnolol for anxiety and stress in healthy adults
Dose
150 mg Magnolol daily
Participants
70 adults with mild-to-moderate stress
Duration
8 weeks
Results
Magnolol significantly reduced STAI anxiety scores and morning cortisol compared to placebo. Sleep quality also improved significantly. No sedation or cognitive impairment observed.
How They Measured It
STAI, PSS-10, cortisol awakening response, PSQI
To investigate GABA-A receptor-mediated anxiolytic effects of Magnolol
Study Type
Animal study
Purpose
To investigate GABA-A receptor-mediated anxiolytic effects of Magnolol
Dose
5-20 mg/kg Magnolol
Participants
28 mice in anxiety paradigms
Duration
Acute and 7-day treatment
Results
Magnolol demonstrated potent anxiolytic activity at 5-20 mg/kg, mediated through GABA-A receptor potentiation at the benzodiazepine binding site, without motor impairment at therapeutic doses.
How They Measured It
Elevated plus maze, light-dark box test, GABA-A receptor assay, benzodiazepine displacement
Metabolic Health
To evaluate Magnolol supplementation on glycemic control in adults with type 2 diabetes
Study Type
Randomised controlled trial
Purpose
To evaluate Magnolol supplementation on glycemic control in adults with type 2 diabetes
Dose
150 mg Magnolol twice daily
Participants
80 adults with type 2 diabetes
Duration
16 weeks
Results
Magnolol as adjunct therapy significantly improved HbA1c (−0.6%), fasting glucose, and HOMA-IR compared to standard therapy alone. LDL cholesterol also modestly reduced. Well tolerated.
How They Measured It
Fasting glucose, HbA1c, insulin, HOMA-IR, lipid panel
To investigate anti-obesity effects of Magnolol in high-fat-fed rodents
Study Type
Animal study
Purpose
To investigate anti-obesity effects of Magnolol in high-fat-fed rodents
Dose
50-200 mg/kg Magnolol
Participants
24 HFD-fed mice
Duration
8 weeks
Results
Magnolol significantly attenuated weight gain, reduced adipose tissue accumulation, improved lipid profiles, increased adiponectin, and favorably modulated gut microbiota composition.
How They Measured It
Body weight, adiposity, lipid profile, adipokines, gut microbiota
Gut Health
To investigate Magnolol effects on gut mucosal barrier function and microbiota
Study Type
Animal study
Purpose
To investigate Magnolol effects on gut mucosal barrier function and microbiota
Dose
50-100 mg/kg Magnolol
Participants
20 mice with DSS-induced colitis
Duration
14 days
Results
Magnolol significantly improved intestinal barrier function, upregulated tight junction proteins, and reduced gut permeability. Anti-inflammatory effects in colonic mucosa confirmed by reduced IL-1β and TNF-α.
How They Measured It
Intestinal permeability (FITC-dextran), tight junction proteins (ZO-1, claudin-1), microbiome 16S rRNA
To evaluate Magnolia extract (Magnolol/Honokiol) for reducing gastrointestinal discomfort in adults with functional GI symptoms
Study Type
Randomised controlled trial
Purpose
To evaluate Magnolia extract (Magnolol/Honokiol) for reducing gastrointestinal discomfort in adults with functional GI symptoms
Dose
200 mg Magnolia extract daily
Participants
60 adults with functional GI symptoms
Duration
8 weeks
Results
Magnolia extract significantly reduced bloating, abdominal discomfort, and normalized stool frequency compared to placebo. GI symptom scores improved by 35% vs 12% in placebo group.
How They Measured It
GI symptom scale, bloating scores, intestinal transit time, stool consistency
To summarize evidence for Magnolol and Honokiol in gastrointestinal and metabolic health
Study Type
Systematic review
Purpose
To summarize evidence for Magnolol and Honokiol in gastrointestinal and metabolic health
Dose
Various formulations reviewed
Participants
Review of 25 studies
Duration
Various
Results
Magnolol demonstrates significant multi-target metabolic effects (antidiabetic, anti-obesity, dyslipidemia), and GI protective effects through gut barrier reinforcement and microbiome modulation. Clinical evidence growing.
How They Measured It
Systematic review of clinical and pre-clinical evidence
Frequently Asked Questions
Common questions about Magnolol research
There are currently 9 peer-reviewed studies on Magnolol (Magnolol), involving 480 total participants. Research covers Anti-inflammatory activity, Anxiety & stress, Metabolic health and 1 more areas. The overall evidence strength is rated as Very Strong.
The evidence is currently rated as "Very Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Magnolol has been researched for: Anti-inflammatory activity, Anxiety & stress, Metabolic health, Gut health. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
